Posts

Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same period in 2021, as well as changes to its pipeline, including a decision to drop a cancer therapeutic developed with Turnstone Biologics.

French healthcare group Sanofi lifted its full-year earnings outlook on continued forecast-beating sales growth for its bestselling drug Dupixent.